Myasthenia gravis: protective effect of ipratropiumbromide (Atrovent) on airways obstruction caused by edrophonium chloride (Tensilon).
The preventive effect of Atrovent Dosier-Aerosol on the airway flow resistance (Raw) caused by Tensilon was studied on 10 patients suffering from myasthenia gravis. Atrovent completely prevented the increase of Raw in 8 cases and considerably decreased it in 2 cases. The measure of the reaction observed may be influenced by the intensity of the cholinergic symptoms occurring on administration of Tensilon as well as by the magnitude of the initial Raw value. No side-effect which may be attributed to the administration of Atrovent could be observed, the substance did not increase the myasthenic symptoms. According to the study, Atrovent is a suitable medicine for the prevention of airway obstruction caused by Tensilon.
D000293:Adolescent; D000328:Adult; D000402:Airway Obstruction / Q000139:chemically induced* / Q000517:prevention & control; D000403:Airway Resistance / Q000187:drug effects; D001286:Atropine Derivatives / Q000627:therapeutic use*; D004491:Edrophonium / Q000009:adverse effects* / Q000627:therapeutic use; D005260:Female; D006801:Humans; D009241:Ipratropium / Q000627:therapeutic use*; D008297:Male; D008875:Middle Aged; D009157:Myasthenia Gravis / Q000188:drug therapy*
D001286:Atropine Derivatives; D004491:Edrophonium; D009241:Ipratropium